Sintilimab Plus a Bevacizumab Biosimilar vs Sorafenib in Unresectable Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sintilimab Plus a Bevacizumab Biosimilar (IBI305) Versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study
Lancet Oncol 2021 Jun 15;[EPub Ahead of Print], Z Ren, J Xu, Y Bai, A Xu, S Cang, C Du, Q Li, Y Lu, Y Chen, Y Guo, Z Chen, B Liu, W Jia, J Wu, J Wang, G Shao, B Zhang, Y Shan, Z Meng, J Wu, S Gu, W Yang, C Liu, X Shi, Z Gao, T Yin, J Cui, M Huang, B Xing, Y Mao, G Teng, Y Qin, J Wang, F Xia, G Yin, Y Yang, M Chen, Y Wang, H Zhou, J FanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.